ClinicalTrials.gg
CompletedNCT02682927Updated Sep 28, 2023Results posted

A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome

A Phase 3 interventional study of ZX008 (Fenfluramine Hydrochloride) and Matching Placebo in Dravet Syndrome and Seizure Disorder, sponsored by Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.. Completed at 55 sites in 11 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
262
Allocation
Randomized
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing fenfluramine in Epilepsies, Myoclonic — 2 open to participants now, 2 under way, none of them phase 3. Fenfluramine · Epilepsies, Myoclonic.

Enrollment
3rd of 11
262 · median 25
Started
2016
with 1 other
Phase 3
7 of 11
none open now
Registered
1st of 11
by date
Lead sponsor
5 of 11
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.

Among the 11 studies testing fenfluramine in Epilepsies, Myoclonic, this one is the 3rd largest by enrollment, is one of 2 that started in 2016, is one of 7 in phase 3, and was the 1st registered.

Epilepsies, Myoclonic

92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.

Browse Epilepsies, Myoclonic studies →

Open to participants now

2 of the 11 studies testing fenfluramine in Epilepsies, Myoclonic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fenfluramine

Fenfluramine: first FDA approval 2020 (FINTEPLA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing fenfluramine in Epilepsies, Myoclonic, or all of them as a file.
02

Study summary

Study 1 and Study 3 are the prospective, merged analyses of 2 identical double-blind, placebo-controlled studies, ZX008-1501 and ZX008-1502, to assess the efficacy, safety, and pharmacokinetics of ZX008 when used as adjunctive therapy in pediatric and young adult subjects with Dravet syndrome. Study 1501 and Study 1502 were conducted in parallel; Study 1501 was conducted at approximately 30 study sites in North America; Study 1502 was conducted at approximately 30 study sites in Europe, Asia and Australia. Upon completion of the Baseline Period after initial Screening and Baseline charting of seizure frequency, subjects who qualified for the studies were randomized (1:1:1) in a double-blind manner to receive either 1 of 2 doses of ZX008 (0.2 mg/kg/day or 0.8 mg/kg/day; maximum dose: 30 mg/day) or placebo. Randomization was stratified by age group (\< 6 years, ≥6 to 18 years) to achieve balance across treatment arms, with the target of 25% of subjects in each age group. All subjects were titrated to their randomized dose over a 14-day Titration Period. Following titration, subjects continued treatment at their randomly assigned dose over a 12-week Maintenance Period. Subjects exiting the study underwent a 2-week taper, unless they enrolled in a follow-on study. Subjects were followed for post-study safety monitoring.

03

Conditions studied

  • Dravet Syndrome
  • Seizure Disorder

Keywords

  • seizure
  • tonic-atonic
  • clonic
  • epilepsy
  • myoclonic
  • encephalopathy
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or non-pregnant, non-lactating female, age 2 to 18 years, inclusive as of the day of the Screening Visit.
  • Clinical diagnosis of Dravet syndrome, where convulsive seizures are not completely controlled by current antiepileptic drugs.
  • Must have a minimum # of convulsive seizures per 4-week period for past 12 weeks prior to screening.
  • All medications or interventions for epilepsy must be stable for at least 4 weeks prior to screening and expected to remain stable throughout the study.
  • No cardiovascular or cardiopulmonary abnormality based on ECHO, or physical examination.
  • Parent/caregiver is willing and able to be compliant with diary completion, visit schedule and study drug accountability.

Key Exclusion Criteria:

  • Pulmonary arterial hypertension.
  • Current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction or stroke.
  • Current or past history of glaucoma.
  • Moderate or severe hepatic impairment.
  • Receiving concomitant therapy with: anorectic agents; monoamine-oxidase inhibitors; medications that act via serotonin including serotonin reuptake inhibitors; atomoxetine, or other centrally-acting noradrenergic agonist; or cyproheptadine.
  • Currently receiving or has received stiripentol in the past 21 days prior to Screening.
  • Currently taking carbamazepine, oxcarbamazepine, eslicarbazepine, phenobarbital, or phenytoin, or has taken any of these within the past 30 days.
  • Positive result on tetrahydrocannabinol (THC) or cannabidiol (CBD) test at the Screening Visit.
  • A medical condition,that would interfere with study participation, collection of study data, or pose a risk to the subject.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
262 participants (actual)

Study arms

  • Experimental
    ZX008 - 0.8 mg/kg/day

    ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.

    Drug: ZX008 (Fenfluramine Hydrochloride)

  • Experimental
    ZX008 - 0.2 mg/kg/day

    ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.

    Drug: ZX008 (Fenfluramine Hydrochloride)

  • Placebo comparator
    Matching Placebo

    Placebo will be administered twice a day (BID) in equally divided doses with food.

    Drug: Matching Placebo

Interventions

  • ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5. The product is sugar free and is intended to be compatible with a ketogenic diet.

  • DrugMatching Placebo

    Placebo solution for ZX008. The product is sugar free and is intended to be compatible with a ketogenic diet.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo

    Monthly (28 day) convulsive seizure frequency (CSF) was based on electronic diary data obtained for each participant. Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). The number of convulsive seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day CSF.

    Time frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]

Secondary outcomes

  1. Change From Baseline in the Mean Convulsive Seizures Frequency to the Combined Titration and Maintenance Period (T+M) in Participants Receiving ZX008 0.2 mg/kg/Day Compared to Placebo

    Monthly (28 day) convulsive seizure frequency (CSF) was based on electronic diary data obtained for each participant. Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). The number of convulsive seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day CSF.

    Time frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]

  2. Percentage of Participants Who Achieved Greater Than or Equal to 25% (≥25%) Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period

    Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). A responder was a participant who experienced a 25% or greater reduction in convulsive seizure frequency per 28 days during Titration and Maintenance Period.

    Time frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]

  3. Percentage of Participants Who Achieved a ≥50% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period

    Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). A responder was a participant who experienced a 50% or greater reduction in convulsive seizure frequency per 28 days during Titration and Maintenance Period.

    Time frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]

  4. Percentage of Participants Who Achieved a ≥75% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period

    Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). A responder was a participant who experienced a 75% or greater reduction in convulsive seizure frequency per 28 days during Titration and Maintenance Period.

    Time frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]

  5. Percentage of Participants Who Achieved a 100% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period

    Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). A responder was a participant who experienced a 100% reduction in convulsive seizure frequency per 28 days during Titration and Maintenance Period.

    Time frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]

  6. Longest Convulsive Seizure-free Interval in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period

    The longest interval between convulsive seizures was calculated over the entire Titration and Maintenance Period and was derived as the maximum of the number of days between consecutive convulsive seizures.

    Time frame: During 14 weeks Titration (2 weeks) and Maintenance Period (12 weeks) (average of 99 days)

  7. Number of Convulsive Seizure-free Days in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period

    A convulsive seizure free day was defined as a day for which diary data are available and no convulsive seizures were reported. Convulsive seizure free days were taken from the electronic diary data.

    Time frame: During 14 weeks Titration (2 weeks) and Maintenance Period (12 weeks) (average of 99 days)

  8. Change From Baseline in Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo

    Non-convulsive seizures included focal without clear observable motor signs, absence or atypical absence, myoclonic and atonic. The number of non-convulsive seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day non-convulsive seizure frequency.

    Time frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]

  9. Change From Baseline in Convulsive + Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo

    Total seizure frequency were defined as the combination of convulsive and non-convulsive seizures. Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). Non-convulsive seizures included focal without clear observable motor signs, absence or atypical absence, myoclonic and atonic. The seizure frequency was based on electronic diary data obtained for each participant. The number of all seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day convulsive or non-convulsive seizure frequency.

    Time frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]

  10. Percentage of Participants With Rescue Medication Usage in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period

    Rescue medication was administered according to each participant's usual or prescribed regimen consisting of 1 or more medications. The usage of rescue medication (number of days and number of medications used per seizure episode) was based on electronic diary data obtained for each participant. The number of days rescue medication was taken (normalized to 28 days) was calculated for each participant. Multiple medications taken on the same day were counted once for that day.

    Time frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]

  11. Percentage of Participants With Hospitalization and Healthcare Resource Utilization to Treat Seizures in Each ZX008 Treatment Arm Compared to Placebo During Study

    Participants who utilized medical center care to treat a seizure during the study were reported.

    Time frame: During 14 weeks Titration (2 weeks) and Maintenance Period (12 weeks) (average of 99 days)

  12. Percentage of Participants With Status Epilepticus (SE) in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period

    The participants who either had SE episode recorded as an adverse event (AE) during treatment or a seizure greater than 10 minutes were reported for each treatment group. Additionally, a single participant who may had more than one episode of SE, and an episode of SE recorded as both an AE and as a seizure longer than 10 minutes was counted as a single event.

    Time frame: During 14 weeks Titration (2 weeks) and Maintenance Period (12 weeks) (average of 99 days)

  13. Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period

    Duration of single convulsive seizures during the Baseline and the duration over the Titration and Maintenance Period were reported by treatment group using categories as \<2 minutes, 2 to 10 minutes and \> 10 minutes as collected in the seizure diary.

    Time frame: At Baseline and 14 weeks of Titration (2 weeks) and Maintenance Period (12 weeks)

  14. Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo

    CGI-I scale measures improvement in the participant's clinical status from Baseline. The severity of a participant's condition was rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), as follows: 1-very much improved,2-much improved, 3-minimally improved, 4- no change, 5-minimally worse, 6-much worse and 7-very much worse. The Principal Investigator rated their global impression of the participant's condition during the study.

    Time frame: At Visit 6 (Day 15), 8 (Day 43), 10 (Day 71) and 12 (Day 99)

  15. Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo

    CGI-I scale measures improvement in the participant's clinical status from Baseline. The severity of a participant's condition was rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), as follows: 1-very much improved,2-much improved, 3-minimally improved, 4- no change, 5-minimally worse, 6-much worse and 7-very much worse. The Parent/Caregiver rated their global impression of the participant's condition during the study.

    Time frame: At Visit 6 (Day 15), 8 (Day 43), 10 (Day 71) and 12 (Day 99)

  16. Change From Baseline to Day 99 in the Quality of Life in Childhood Epilepsy (QOLCE) Score to Measure Quality of Life in Each ZX008 Treatment Arm Compared to Placebo

    QOLCE is a low-burden parent/caregiver completed assessment that evaluates how epilepsy affects day-to day functioning of the participant in various life areas, including physical activities, well being, cognition, social activities, behavior, and general health. QOLCE scores items on 16 subscales with possible 5-point response for each, where scores of 5 was best possible response and 1 was worst possible response. Item scores were then transformed to a 0-100 scale as follows: 1-0, 2-25, 3-50, 4-75, 5-100. A score for each participant for each subscale was calculated by averaging that participant's responses to each item in the subscale. Subscale scores per participant were averaged to obtain an overall QoL score for each participant. Higher the subscale and overall QoL scores, better the response.

    Time frame: From Baseline to Day 99

  17. Change From Baseline to Day 99 in the Overall Quality of Life Score From the Pediatric Quality of Life Inventory™ (PedsQL) Score in Each ZX008 Treatment Arm Compared to Placebo

    The Pediatric Quality of Life Inventory (PedsQL) is a pediatric modular measure of health related quality of life (QoL) completed by the parent/caregiver on behalf of the participant. It consisted of 23 items across 4 core scales that measure physical (8 items), emotional, social, and school functioning (5 items each). Each of the responses to the 23 items is initially scored on a 5-point Likert scale from 0 (Never) to 4 (Almost always). Scores are linearly transformed to a scale of 0 to 100, where 0=100, 1=75, 2=50, 3=25 and 4=0, and higher scores correspond to better health-related QoL. The Overall Quality of Life is the average of all the items over the number of items answered on all the Scales.

    Time frame: From Baseline to Day 99

  18. Change From Baseline to Day 99 in the Total Score From PedsQL Family Impact Module Score in Each ZX008 Treatment Arm Compared to Placebo

    The PedsQL Family Impact measured the impact of pediatric chronic health conditions on parents and the family by measuring parent self-reported physical, emotional, social, and cognitive functioning, communication, worry, and family daily activities and relationships. There are a total of 36 items in the PedsQL: 6 items for Physical Functioning, 5 items each for Emotional Functioning, Cognitive Functioning and Worry, 4 for Social Functioning, 3 for Communication, 3 questions for Daily Activities, and 5 for Family Relationships. Each of the responses are initially scored on a 5-point Likert scale from 0 (Never) to 4 (Almost always) and then linearly transformed to a scale of 0 to 100, where 0=100, 1=75, 2=50, 3=25 and 4=0, and higher scores mean better health-related QoL.

    Time frame: From Baseline to Day 99

  19. Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99

    The EuroQOL-5 Dimensions-5 Levels scale produced by European QOL Group (EQ-5D-5L) health questionnaire is a health-related QOL instrument with 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The 5 dimensions of EQ-5D-5L health questionnaire were assessed on a Likert scale with 5 possible levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The categories "slight problems", "moderate problems", "severe problems" and "extreme problems" are collapsed into one response category "problems. The QOL of the parent/caregiver was assessed and percentage of participants was reported for each item.

    Time frame: At Baseline and Day 99

  20. Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo

    The HADS is a tool that was validated to assess presence of anxiety or depression in an outpatient non-psychiatric population. The HADS a 14-item scale that generates ordinal data for 2 dimensions: 1) Anxiety (7 items), and 2) Depression (7 items). Each item has 4 possible answers rated 0 to 3, of which 0 = No distress and 3 = worst distress. All answers to the items for a dimension with their respective rating are added resulting in a range for each dimension from 0-21, out of which of 0-7 = normal; 8-10=borderline abnormal; 11-21=abnormal. Scores for the entire scale (emotional distress) range from 0 to 42, with higher scores indicating more distress.

    Time frame: From Baseline to Day 99

  21. Maximum Observed Concentration of ZX008 Determined Directly From the Concentration Time Profile [Cmax] at Steady State

    Cmax is the maximum observed concentration determined directly from the concentration-time profile.

    Time frame: At Visit 8 (Day 43): pre-dose, 1, 2, and 4-6 hours postdose

  22. Area Under the Concentration Time Curve of ZX008 From Time Zero to Time 24 Hours [AUC0-24hours] at Steady State

    AUC0-24 is the area under the concentration time curve from time zero to 24 hours.

    Time frame: At Visit 8 (Day 43): pre-dose, 1, 2, and 4-6 hours postdose

  23. Time to Maximum Concentration [Tmax] of ZX008 at Steady State

    Tmax is the time to maximum concentration at steady state.

    Time frame: At Visit 8 (Day 43): pre-dose, 1, 2, and 4-6 hours postdose

  24. Elimination Half-life [t1/2 Beta] of ZX008 at Steady State

    t1/2 beta is the elimination half-life.

    Time frame: At Visit 8 (Day 43): pre-dose, 1, 2, and 4-6 hours postdose

07

Results

Posted Oct 19, 2022
Limitations and caveats
The full results posting consists of the pooled analysis 1 and 2 of the studies with study ID ZX008-1501 and ZX008-1502. Pooled analysis 1 is referenced as Study 1 in the respective statistical analysis plan (SAP) and corresponding clinical study report (CSR). Pooled analysis 2 is referenced as Study 2 in the respective SAP and, due to the timing of regulatory submissions, Study 3 in the corresponding CSR and in this results posting.

Participant flow

The study 1501 started to enroll participants in January 2016 and concluded in July 2020. The study 1502 started to enroll participants in July 2016 and concluded in July 2020. The consolidated results of Study 1 and Study 3 are included in this record. The Participant Flow refers to the Randomized Population.

Participant flow — Overall Study
MilestoneStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Started403940484649
Completed373934434546
Not completed306513
Withdrew: Adverse event005102
Withdrew: Death000100
Withdrew: Lack of efficacy100100
Withdrew: Other000200
Withdrew: Withdrawal by subject201011

Outcome measures

PrimaryChange From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo

Monthly (28 day) convulsive seizure frequency (CSF) was based on electronic diary data obtained for each participant. Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). The number of convulsive seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day CSF.

Time frame:
From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Reported as:
Mean · seizure frequency per 28 days
Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo
seizure frequency per 28 daysStudy 1: PlaceboStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.8 mg/kg/Day
Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo-6.71 ± 24.263-13.11 ± 25.5001.54 ± 21.966-3.54 ± 124.132
Statistical analysis
  • Study 1: Placebo vs Study 1: ZX008 0.8 mg/kg/Day · Percentage difference from placebo: 62.29 · 95% CI 47.72 to 72.80Estimate was obtained from the LSMeans on the log scale as follows: 100 x \[1 - exp(LS mean active - LS mean placebo).
  • Study 3: Placebo vs Study 3: ZX008 0.8 mg/kg/Day · Percentage difference from placebo: 64.75 · 95% CI 51.85 to 74.19Estimate was obtained from the LSMeans on the log scale as follows: 100 x \[1 - exp(LS mean active - LS mean placebo).
SecondaryChange From Baseline in the Mean Convulsive Seizures Frequency to the Combined Titration and Maintenance Period (T+M) in Participants Receiving ZX008 0.2 mg/kg/Day Compared to Placebo

Monthly (28 day) convulsive seizure frequency (CSF) was based on electronic diary data obtained for each participant. Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). The number of convulsive seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day CSF.

Time frame:
From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Reported as:
Mean · seizure frequency per 28 days
Change From Baseline in the Mean Convulsive Seizures Frequency to the Combined Titration and Maintenance Period (T+M) in Participants Receiving ZX008 0.2 mg/kg/Day Compared to Placebo
seizure frequency per 28 daysStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/Day
Change From Baseline in the Mean Convulsive Seizures Frequency to the Combined Titration and Maintenance Period (T+M) in Participants Receiving ZX008 0.2 mg/kg/Day Compared to Placebo-6.71 ± 24.263-18.81 ± 90.6401.54 ± 21.966-5.89 ± 84.735
Statistical analysis
  • Study 1: Placebo vs Study 1: ZX008 0.2 mg/kg/Day · Percentage difference from placebo: 32.43 · 95% CI 6.19 to 51.33Estimate was obtained from the LSMeans on the log scale as follows: 100 x \[1 - exp(LS mean active - LS mean placebo).
  • Study 3: Placebo vs Study 3: ZX008 0.2 mg/kg/Day · Percentage difference from placebo: 49.88 · 95% CI 31.31 to 63.43Estimate was obtained from the LSMeans on the log scale as follows: 100 x \[1 - exp(LS mean active - LS mean placebo).
SecondaryPercentage of Participants Who Achieved Greater Than or Equal to 25% (≥25%) Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period

Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). A responder was a participant who experienced a 25% or greater reduction in convulsive seizure frequency per 28 days during Titration and Maintenance Period.

Time frame:
From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Greater Than or Equal to 25% (≥25%) Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period
percentage of participantsStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Percentage of Participants Who Achieved Greater Than or Equal to 25% (≥25%) Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period35.066.790.027.171.783.3
SecondaryPercentage of Participants Who Achieved a ≥50% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period

Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). A responder was a participant who experienced a 50% or greater reduction in convulsive seizure frequency per 28 days during Titration and Maintenance Period.

Time frame:
From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a ≥50% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period
percentage of participantsStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Percentage of Participants Who Achieved a ≥50% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period12.538.567.56.345.772.9
Statistical analysis
  • Study 1: Placebo vs Study 1: ZX008 0.2 mg/kg/Day · Regression, Logistic · p = 0.009 · Odds ratio (or): 4.773 · 95% CI 1.475 to 15.450
  • Study 1: Placebo vs Study 1: ZX008 0.8 mg/kg/Day · Regression, Logistic · p = <0.001 · Odds ratio (or): 14.960 · 95% CI 4.484 to 49.915
  • Study 3: Placebo vs Study 3: ZX008 0.2 mg/kg/Day · Regression, Logistic · p = 0.0001 · Odds ratio (or): 13.4 · 95% CI 3.6 to 49.8
  • Study 3: Placebo vs Study 3: ZX008 0.8 mg/kg/Day · Regression, Logistic · p = <0.0001 · Odds ratio (or): 53.3 · 95% CI 12.9 to 220.5
SecondaryPercentage of Participants Who Achieved a ≥75% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period

Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). A responder was a participant who experienced a 75% or greater reduction in convulsive seizure frequency per 28 days during Titration and Maintenance Period.

Time frame:
From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a ≥75% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period
percentage of participantsStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Percentage of Participants Who Achieved a ≥75% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period2.523.150.04.228.347.9
SecondaryPercentage of Participants Who Achieved a 100% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period

Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). A responder was a participant who experienced a 100% reduction in convulsive seizure frequency per 28 days during Titration and Maintenance Period.

Time frame:
From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a 100% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period
percentage of participantsStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Percentage of Participants Who Achieved a 100% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period07.77.50012.5
SecondaryLongest Convulsive Seizure-free Interval in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period

The longest interval between convulsive seizures was calculated over the entire Titration and Maintenance Period and was derived as the maximum of the number of days between consecutive convulsive seizures.

Time frame:
During 14 weeks Titration (2 weeks) and Maintenance Period (12 weeks) (average of 99 days)
Reported as:
Median · days
Longest Convulsive Seizure-free Interval in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period
daysStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Longest Convulsive Seizure-free Interval in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period9.50 (2.0 to 23.0)15.00 (3.0 to 106.0)25.00 (2.0 to 97.0)10 (2 to 65)18.5 (2 to 100)30 (2 to 104)
Statistical analysis
  • Study 1: Placebo vs Study 1: ZX008 0.2 mg/kg/Day · Wilcoxon rank sum test · p = 0.035
  • Study 1: Placebo vs Study 1: ZX008 0.8 mg/kg/Day · Wilcoxon rank sum test · p = <0.001
  • Study 3: Placebo vs Study 3: ZX008 0.2 mg/kg/Day · Wilcoxon rank sum test · p = 0.0002
  • Study 3: Placebo vs Study 3: ZX008 0.8 mg/kg/Day · Wilcoxon rank sum test · p = <0.0001
SecondaryNumber of Convulsive Seizure-free Days in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period

A convulsive seizure free day was defined as a day for which diary data are available and no convulsive seizures were reported. Convulsive seizure free days were taken from the electronic diary data.

Time frame:
During 14 weeks Titration (2 weeks) and Maintenance Period (12 weeks) (average of 99 days)
Reported as:
Median · seizure free days
Number of Convulsive Seizure-free Days in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period
seizure free daysStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Number of Convulsive Seizure-free Days in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period15.14 (1.1 to 25.6)20.86 (2.2 to 28.0)24.43 (1.0 to 28.0)20.20 (1.4 to 27.1)23.36 (0.8 to 27.7)25.33 (0.3 to 28.0)
SecondaryChange From Baseline in Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo

Non-convulsive seizures included focal without clear observable motor signs, absence or atypical absence, myoclonic and atonic. The number of non-convulsive seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day non-convulsive seizure frequency.

Time frame:
From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Reported as:
Median · seizure frequency per 28 days
Change From Baseline in Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo
seizure frequency per 28 daysStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Change From Baseline in Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo-9.38 (-198.8 to 1886.1)-4.85 (-1940.8 to 192.3)-20.06 (-2064.8 to 9.4)-0.68 (-160.0 to 1313.1)-0.67 (-138.7 to 111.3)-4.35 (-1410.6 to 107.5)
SecondaryChange From Baseline in Convulsive + Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo

Total seizure frequency were defined as the combination of convulsive and non-convulsive seizures. Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). Non-convulsive seizures included focal without clear observable motor signs, absence or atypical absence, myoclonic and atonic. The seizure frequency was based on electronic diary data obtained for each participant. The number of all seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day convulsive or non-convulsive seizure frequency.

Time frame:
From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Reported as:
Median · seizure frequency per 28 days
Change From Baseline in Convulsive + Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo
seizure frequency per 28 daysStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Change From Baseline in Convulsive + Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo-4.45 (-198.4 to 1850.1)-7.40 (-1955.1 to 187.1)-22.95 (-2069.3 to 44.5)-1.09 (-160.1 to 1310.5)-6.54 (-153.0 to 525.9)-11.39 (-1504.8 to 791.4)
SecondaryPercentage of Participants With Rescue Medication Usage in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period

Rescue medication was administered according to each participant's usual or prescribed regimen consisting of 1 or more medications. The usage of rescue medication (number of days and number of medications used per seizure episode) was based on electronic diary data obtained for each participant. The number of days rescue medication was taken (normalized to 28 days) was calculated for each participant. Multiple medications taken on the same day were counted once for that day.

Time frame:
From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Reported as:
Number · percentage of participants
Percentage of Participants With Rescue Medication Usage in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period
percentage of participantsStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Percentage of Participants With Rescue Medication Usage in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period77.559.045.060.465.247.9
SecondaryPercentage of Participants With Hospitalization and Healthcare Resource Utilization to Treat Seizures in Each ZX008 Treatment Arm Compared to Placebo During Study

Participants who utilized medical center care to treat a seizure during the study were reported.

Time frame:
During 14 weeks Titration (2 weeks) and Maintenance Period (12 weeks) (average of 99 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Hospitalization and Healthcare Resource Utilization to Treat Seizures in Each ZX008 Treatment Arm Compared to Placebo During Study
percentage of participantsStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Percentage of Participants With Hospitalization and Healthcare Resource Utilization to Treat Seizures in Each ZX008 Treatment Arm Compared to Placebo During Study22.517.915.012.519.614.6
SecondaryPercentage of Participants With Status Epilepticus (SE) in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period

The participants who either had SE episode recorded as an adverse event (AE) during treatment or a seizure greater than 10 minutes were reported for each treatment group. Additionally, a single participant who may had more than one episode of SE, and an episode of SE recorded as both an AE and as a seizure longer than 10 minutes was counted as a single event.

Time frame:
During 14 weeks Titration (2 weeks) and Maintenance Period (12 weeks) (average of 99 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Status Epilepticus (SE) in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period
percentage of participantsStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Percentage of Participants With Status Epilepticus (SE) in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period27.528.235.016.719.625.0
SecondaryDistribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period

Duration of single convulsive seizures during the Baseline and the duration over the Titration and Maintenance Period were reported by treatment group using categories as \<2 minutes, 2 to 10 minutes and \> 10 minutes as collected in the seizure diary.

Time frame:
At Baseline and 14 weeks of Titration (2 weeks) and Maintenance Period (12 weeks)
Reported as:
Number · percentage of seizures
Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period
percentage of seizuresStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
<2 min (Baseline)69.2864.1371.6164.2163.9074.11
2-10 min (Baseline)26.8634.9524.2234.8333.6622.78
>10 min (Baseline)3.860.934.170.962.453.10
<2 min (Titration + Maintenance Period)71.3171.5972.2765.8463.4584.67
2-10 min (Titration + Maintenance Period)26.3125.6122.9133.7431.3413.71
>10 min (Titration + Maintenance Period)2.382.794.820.435.221.62
SecondaryPercentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo

CGI-I scale measures improvement in the participant's clinical status from Baseline. The severity of a participant's condition was rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), as follows: 1-very much improved,2-much improved, 3-minimally improved, 4- no change, 5-minimally worse, 6-much worse and 7-very much worse. The Principal Investigator rated their global impression of the participant's condition during the study.

Time frame:
At Visit 6 (Day 15), 8 (Day 43), 10 (Day 71) and 12 (Day 99)
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo
percentage of participantsStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
1 = Very much improved (Visit 6)5.023.117.54.221.716.7
2 = Much improved (Visit 6)12.512.825.02.121.727.1
3 = Minimally improved (Visit 6)20.020.520.027.117.427.1
4 = No change (Visit 6)40.025.617.554.226.112.5
5 = Minimally worse (Visit 6)5.07.75.04.22.22.1
6 = Much worse (Visit 6)002.5004.2
7 = Very much worse (Visit 6)000000
1 = Very much improved (Visit 8)05.117.54.217.429.2
2 = Much improved (Visit 8)12.530.837.56.310.931.3
3 = Minimally improved (Visit 8)30.020.510.016.726.114.6
4 = No change (Visit 8)30.017.910.050.034.88.3
5 = Minimally worse (Visit 8)5.05.104.204.2
6 = Much worse (Visit 8)2.55.12.52.100
7 = Very much worse (Visit 8)002.5000
1 = Very much improved (Visit 10)2.517.920.04.215.235.4
2 = Much improved (Visit 10)7.517.947.510.419.618.8
3 = Minimally improved (Visit 10)30.025.65.012.526.116.7
4 = No change (Visit 10)35.028.27.560.428.34.2
5 = Minimally worse (Visit 10)10.07.70000
6 = Much worse (Visit 10)02.60002.1
7 = Very much worse (Visit 10)000000
1 = Very much improved (Visit 12)2.512.827.54.28.733.3
2 = Much improved (Visit 12)7.528.235.04.228.331.3
3 = Minimally improved (Visit 12)30.017.915.016.721.710.4
4 = No change (Visit 12)47.528.212.558.328.316.7
5 = Minimally worse (Visit 12)2.510.306.310.96.3
6 = Much worse (Visit 12)2.52.60000
7 = Very much worse (Visit 12)002.5000
SecondaryPercentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo

CGI-I scale measures improvement in the participant's clinical status from Baseline. The severity of a participant's condition was rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), as follows: 1-very much improved,2-much improved, 3-minimally improved, 4- no change, 5-minimally worse, 6-much worse and 7-very much worse. The Parent/Caregiver rated their global impression of the participant's condition during the study.

Time frame:
At Visit 6 (Day 15), 8 (Day 43), 10 (Day 71) and 12 (Day 99)
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo
percentage of participantsStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
1 = Very much improved (Visit 6)2.517.915.06.313.016.7
2 = Much improved (Visit 6)22.520.527.52.123.931.3
3 = Minimally improved (Visit 6)12.528.222.525.026.131.3
4 = No change (Visit 6)45.012.820.045.819.62.1
5 = Minimally worse (Visit 6)2.57.72.510.42.26.3
6 = Much worse (Visit 6)5.02.67.52.12.22.1
7 = Very much worse (Visit 6)002.5002.1
1 = Very much improved (Visit 8)015.420.04.26.539.6
2 = Much improved (Visit 8)15.025.637.58.330.429.2
3 = Minimally improved (Visit 8)25.025.615.020.828.314.6
4 = No change (Visit 8)20.012.85.047.917.46.3
5 = Minimally worse (Visit 8)15.010.32.56.36.50
6 = Much worse (Visit 8)2.55.15.04.22.22.1
7 = Very much worse (Visit 8)002.54.200
1 = Very much improved (Visit 10)2.520.535.02.18.741.7
2 = Much improved (Visit 10)12.517.930.06.328.322.9
3 = Minimally improved (Visit 10)22.520.57.525.026.18.3
4 = No change (Visit 10)32.525.610.045.826.16.3
5 = Minimally worse (Visit 10)12.57.706.304.2
6 = Much worse (Visit 10)2.57.7004.30
7 = Very much worse (Visit 10)2.502.5000
1 = Very much improved (Visit 12)2.520.527.52.16.533.3
2 = Much improved (Visit 12)7.520.527.56.328.329.2
3 = Minimally improved (Visit 12)20.015.410.018.830.420.8
4 = No change (Visit 12)35.020.515.050.013.04.2
5 = Minimally worse (Visit 12)17.515.45.010.48.74.2
6 = Much worse (Visit 12)7.57.75.02.14.32.1
7 = Very much worse (Visit 12)002.502.22.1
SecondaryChange From Baseline to Day 99 in the Quality of Life in Childhood Epilepsy (QOLCE) Score to Measure Quality of Life in Each ZX008 Treatment Arm Compared to Placebo

QOLCE is a low-burden parent/caregiver completed assessment that evaluates how epilepsy affects day-to day functioning of the participant in various life areas, including physical activities, well being, cognition, social activities, behavior, and general health. QOLCE scores items on 16 subscales with possible 5-point response for each, where scores of 5 was best possible response and 1 was worst possible response. Item scores were then transformed to a 0-100 scale as follows: 1-0, 2-25, 3-50, 4-75, 5-100. A score for each participant for each subscale was calculated by averaging that participant's responses to each item in the subscale. Subscale scores per participant were averaged to obtain an overall QoL score for each participant. Higher the subscale and overall QoL scores, better the response.

Time frame:
From Baseline to Day 99
Reported as:
Mean · score on a scale
Change From Baseline to Day 99 in the Quality of Life in Childhood Epilepsy (QOLCE) Score to Measure Quality of Life in Each ZX008 Treatment Arm Compared to Placebo
score on a scaleStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Change From Baseline to Day 99 in the Quality of Life in Childhood Epilepsy (QOLCE) Score to Measure Quality of Life in Each ZX008 Treatment Arm Compared to Placebo1.5 ± 8.730.8 ± 11.775.8 ± 11.701.2 ± 9.016.1 ± 12.475.5 ± 13.22
SecondaryChange From Baseline to Day 99 in the Overall Quality of Life Score From the Pediatric Quality of Life Inventory™ (PedsQL) Score in Each ZX008 Treatment Arm Compared to Placebo

The Pediatric Quality of Life Inventory (PedsQL) is a pediatric modular measure of health related quality of life (QoL) completed by the parent/caregiver on behalf of the participant. It consisted of 23 items across 4 core scales that measure physical (8 items), emotional, social, and school functioning (5 items each). Each of the responses to the 23 items is initially scored on a 5-point Likert scale from 0 (Never) to 4 (Almost always). Scores are linearly transformed to a scale of 0 to 100, where 0=100, 1=75, 2=50, 3=25 and 4=0, and higher scores correspond to better health-related QoL. The Overall Quality of Life is the average of all the items over the number of items answered on all the Scales.

Time frame:
From Baseline to Day 99
Reported as:
Mean · score on a scale
Change From Baseline to Day 99 in the Overall Quality of Life Score From the Pediatric Quality of Life Inventory™ (PedsQL) Score in Each ZX008 Treatment Arm Compared to Placebo
score on a scaleStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Change From Baseline to Day 99 in the Overall Quality of Life Score From the Pediatric Quality of Life Inventory™ (PedsQL) Score in Each ZX008 Treatment Arm Compared to Placebo-1.6 ± 10.436.8 ± 11.255.9 ± 15.111.9 ± 13.264.2 ± 17.652.1 ± 14.73
SecondaryChange From Baseline to Day 99 in the Total Score From PedsQL Family Impact Module Score in Each ZX008 Treatment Arm Compared to Placebo

The PedsQL Family Impact measured the impact of pediatric chronic health conditions on parents and the family by measuring parent self-reported physical, emotional, social, and cognitive functioning, communication, worry, and family daily activities and relationships. There are a total of 36 items in the PedsQL: 6 items for Physical Functioning, 5 items each for Emotional Functioning, Cognitive Functioning and Worry, 4 for Social Functioning, 3 for Communication, 3 questions for Daily Activities, and 5 for Family Relationships. Each of the responses are initially scored on a 5-point Likert scale from 0 (Never) to 4 (Almost always) and then linearly transformed to a scale of 0 to 100, where 0=100, 1=75, 2=50, 3=25 and 4=0, and higher scores mean better health-related QoL.

Time frame:
From Baseline to Day 99
Reported as:
Mean · score on a scale
Change From Baseline to Day 99 in the Total Score From PedsQL Family Impact Module Score in Each ZX008 Treatment Arm Compared to Placebo
score on a scaleStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Change From Baseline to Day 99 in the Total Score From PedsQL Family Impact Module Score in Each ZX008 Treatment Arm Compared to Placebo-4.4 ± 13.003.9 ± 9.445.4 ± 15.601.3 ± 14.880.7 ± 15.786.3 ± 14.64
SecondaryQuality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99

The EuroQOL-5 Dimensions-5 Levels scale produced by European QOL Group (EQ-5D-5L) health questionnaire is a health-related QOL instrument with 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The 5 dimensions of EQ-5D-5L health questionnaire were assessed on a Likert scale with 5 possible levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The categories "slight problems", "moderate problems", "severe problems" and "extreme problems" are collapsed into one response category "problems. The QOL of the parent/caregiver was assessed and percentage of participants was reported for each item.

Time frame:
At Baseline and Day 99
Reported as:
Number · percentage of participants
Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99
percentage of participantsStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Mobility- No problems (Baseline)33.3352.9446.1540.0054.5528.57
Mobility- Problems (Baseline)66.6747.0653.8560.0045.4571.43
Mobility- No problems (Day 99)40.0045.9551.3552.3851.1646.67
Mobility- Problems (Day 99)60.0054.0548.6547.6248.8453.33
Self-care - No problems (Baseline)25.6441.1838.4622.5036.3622.86
Self-care - Problems (Baseline)74.3658.8261.5477.5063.6477.14
Self-care - No problems (Day 99)28.5743.2448.6530.9534.8835.56
Self-care - Problems (Day 99)71.4356.7651.3569.0565.1264.44
Usual activities- No problems (Baseline)23.0841.1835.9025.0039.3920.00
Usual activities- Problems (Baseline)76.9258.8264.1075.0060.6180.00
Usual activities- No problems (Day 99)25.7132.4348.6530.9525.5835.56
Usual activities- Problems (Day 99)74.2967.5751.3569.0574.4264.44
Pain/discomfort- No problems (Baseline)48.7241.1846.1545.0051.5251.43
Pain/discomfort- Problems (Baseline)51.2858.8253.8555.0048.4848.57
Pain/discomfort- No problems (Day 99)48.5751.3564.8676.1946.5164.44
Pain/discomfort- Problems (Day 99)51.4348.6535.1445.2453.4935.56
Anxiety/depression- No problems (Baseline)74.3661.7656.4160.0063.6474.29
Anxiety/depression- Problems (Baseline)25.6438.2443.5940.0036.3625.71
Anxiety/depression- No problems (Day 99)65.7167.5767.5769.0567.4473.33
Anxiety/depression- Problems (Day 99)34.2932.4332.4330.9532.5626.67
SecondaryChange From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo

The HADS is a tool that was validated to assess presence of anxiety or depression in an outpatient non-psychiatric population. The HADS a 14-item scale that generates ordinal data for 2 dimensions: 1) Anxiety (7 items), and 2) Depression (7 items). Each item has 4 possible answers rated 0 to 3, of which 0 = No distress and 3 = worst distress. All answers to the items for a dimension with their respective rating are added resulting in a range for each dimension from 0-21, out of which of 0-7 = normal; 8-10=borderline abnormal; 11-21=abnormal. Scores for the entire scale (emotional distress) range from 0 to 42, with higher scores indicating more distress.

Time frame:
From Baseline to Day 99
Reported as:
Mean · score on a scale
Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo
score on a scaleStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Anxiety-0.4 ± 2.68-0.8 ± 2.84-0.8 ± 3.33-0.6 ± 3.620.2 ± 3.89-0.7 ± 4.00
Depression0.8 ± 4.500.2 ± 4.520.1 ± 4.35-0.7 ± 3.802.0 ± 4.77-0.8 ± 4.03
Total emotional distress0.4 ± 6.45-0.6 ± 6.60-0.7 ± 6.82-1.2 ± 6.422.2 ± 7.52-1.5 ± 6.61
SecondaryMaximum Observed Concentration of ZX008 Determined Directly From the Concentration Time Profile [Cmax] at Steady State

Cmax is the maximum observed concentration determined directly from the concentration-time profile.

Time frame:
At Visit 8 (Day 43): pre-dose, 1, 2, and 4-6 hours postdose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Maximum Observed Concentration of ZX008 Determined Directly From the Concentration Time Profile [Cmax] at Steady State
nanograms per milliliter (ng/mL)Study 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Maximum Observed Concentration of ZX008 Determined Directly From the Concentration Time Profile [Cmax] at Steady State17.7 ± 32.567.9 ± 37.417.4 ± 32.364.5 ± 36.6
SecondaryArea Under the Concentration Time Curve of ZX008 From Time Zero to Time 24 Hours [AUC0-24hours] at Steady State

AUC0-24 is the area under the concentration time curve from time zero to 24 hours.

Time frame:
At Visit 8 (Day 43): pre-dose, 1, 2, and 4-6 hours postdose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
Area Under the Concentration Time Curve of ZX008 From Time Zero to Time 24 Hours [AUC0-24hours] at Steady State
nanogram*hour per milliliter (ng*h/mL)Study 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Area Under the Concentration Time Curve of ZX008 From Time Zero to Time 24 Hours [AUC0-24hours] at Steady State356 ± 37.01390 ± 41.3348 ± 37.11290 ± 42.6
SecondaryTime to Maximum Concentration [Tmax] of ZX008 at Steady State

Tmax is the time to maximum concentration at steady state.

Time frame:
At Visit 8 (Day 43): pre-dose, 1, 2, and 4-6 hours postdose
Reported as:
Median · hours (h)
Time to Maximum Concentration [Tmax] of ZX008 at Steady State
hours (h)Study 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Time to Maximum Concentration [Tmax] of ZX008 at Steady State2.90 (2.80 to 3.10)3.00 (2.70 to 3.20)2.90 (2.80 to 3.10)2.90 (2.70 to 3.20)
SecondaryElimination Half-life [t1/2 Beta] of ZX008 at Steady State

t1/2 beta is the elimination half-life.

Time frame:
At Visit 8 (Day 43): pre-dose, 1, 2, and 4-6 hours postdose
Reported as:
Geometric mean · hours (h)
Elimination Half-life [t1/2 Beta] of ZX008 at Steady State
hours (h)Study 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Elimination Half-life [t1/2 Beta] of ZX008 at Steady State18.4 ± 32.321.1 ± 51.818.1 ± 32.118.6 ± 42.2

Adverse events

Collected over From Titration Period until the Safety Follow-up Visit (up to Day 113). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Study 1: Placebo0/40 (0%)4/40 (10%)22/40 (55%)
Study 1: ZX008 0.2 mg/kg/Day0/39 (0%)4/39 (10.3%)35/39 (89.7%)
Study 1: ZX008 0.8 mg/kg/Day0/40 (0%)5/40 (12.5%)36/40 (90%)
Study 3: Placebo1/48 (2.1%)2/48 (4.2%)37/48 (77.1%)
Study 3: ZX008 0.2 mg/kg/Day0/46 (0%)3/46 (6.5%)41/46 (89.1%)
Study 3: ZX008 0.8 mg/kg/Day0/48 (0%)3/48 (6.3%)41/48 (85.4%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Status epilepticusNervous system disorders2/401/392/400/481/460/48
Lower respiratory tract infectionInfections and infestations0/401/390/401/480/460/48
SeizureNervous system disorders1/401/391/401/481/460/48
HypoxiaRespiratory, thoracic and mediastinal disorders0/401/390/400/480/460/48
DiarrhoeaGastrointestinal disorders0/400/391/400/480/460/48
Adverse drug reactionGeneral disorders0/400/391/400/480/460/48
PneumoniaInfections and infestations1/400/390/400/480/460/48
Head injuryInjury, poisoning and procedural complications1/400/390/400/480/460/48
Weight decreasedInvestigations0/400/391/400/480/460/48
Decreased appetiteMetabolism and nutrition disorders0/400/391/400/480/460/48
Most frequent other events
Showing 10 of 49
Most frequent other events
EventStudy 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/Day
Decreased appetiteMetabolism and nutrition disorders2/408/3914/403/4812/4618/48
DiarrhoeaGastrointestinal disorders3/4012/397/404/487/467/48
Blood glucose decreasedInvestigations0/400/390/406/4811/468/48
Echocardiogram abnormalInvestigations5/407/399/405/4811/468/48
SomnolenceNervous system disorders3/406/393/405/485/4610/48
Upper respiratory tract infectionInfections and infestations5/408/390/402/483/464/48
PyrexiaGeneral disorders8/407/392/404/485/469/48
NasopharyngitisInfections and infestations5/404/397/405/484/461/48
LethargyNervous system disorders2/404/397/402/481/463/48
Weight decreasedInvestigations0/405/391/400/481/464/48

Baseline characteristics

Baseline characteristics refers to the Randomized population which included all participants randomized to receive study treatment.

Age, Continuous
Age, Continuous(years)Study 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/DayTotal
Mean9.2 ± 5.109.0 ± 4.528.8 ± 4.419.0 ± 4.299.6 ± 4.429.5 ± 5.299.2 ± 4.65
Age, Customized
Age, Customized(Participants)Study 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/DayTotal
24 Months - <12 Years272831313030177
12 - < 18 Years1011717151676
18 - < 65 Years3020139
Sex: Female, Male
Sex: Female, Male(Participants)Study 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/DayTotal
Female191719212227125
Male212221272422137
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Study 1: PlaceboStudy 1: ZX008 0.2 mg/kg/DayStudy 1: ZX008 0.8 mg/kg/DayStudy 3: PlaceboStudy 3: ZX008 0.2 mg/kg/DayStudy 3: ZX008 0.8 mg/kg/DayTotal
White313334363734205
Black or African American0000112
Asian42175827
American Indian or Alaska Native1100002
Other21142313
Not Reported22410110
Unknown0000123
08

Study locations

55 sites
  • Phoenix Children's
    Phoenix, Arizona 85016, United States
  • Center for Neurosciences - Tucson
    Tucson, Arizona 85718, United States
  • Rady Children's Hospital San Diego
    San Diego, California 92123, United States
  • University of California San Francisco
    San Francisco, California 94143, United States
  • The Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • NW FL Clinical Research Group, LLC
    Gulf Breeze, Florida 32561, United States
  • Miami Children's Hospital Brain Institute
    Miami, Florida 33155, United States
  • Neurology and Epilepsy Research Center
    Orlando, Florida 32819, United States
  • Panda Neurology
    Atlanta, Georgia 30328, United States
  • Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02467, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Saint Barnabas Medical Center
    Livingston, New Jersey 07039, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Cook Children's Medical Center
    Fort Worth, Texas 76087, United States
  • University of Utah
    Salt Lake City, Utah 84113, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • MultiCare Institute for Research & Innovation
    Tacoma, Washington 98405, United States
  • Melbourne Brain Centre Austin Hospital
    Melbourne, Australia
  • Children's Health Queensland Hospital and Health Service at Lady Cilento Children's Hospital
    South Brisbane, Australia
  • The Children's Hospital Westmead Dept. of Neurology and Neurosurgery
    Westmead, Australia
  • Universitair Ziekenhuis Antwerpen
    Antwerp, Belgium
  • British Columbia Children's Hospital BCCH
    Vancouver, British Columbia V6H3V4, Canada
  • Centre Hospitalier Universitaire Sainte-Justine
    Montréal, H3T 1C5, Canada
  • Danish National Epilepsy Centre
    Dianalund, Denmark
  • French Ref centre Necker Hospital Paris
    Paris, France
  • Epilepsiezentrum / Neuropädiatrie Hedwig-von-Rittberg-Zentrum Für Kinder und Jugendliche
    Berlin, Germany
  • Krankenhaus Mara Epilepsie-Zentrum Bethel
    Bielefeld, Germany
  • Epilepsiezentrum Freiburg
    Freiburg, Germany
  • Universitaetsklinikum Jena Klinik fuer Kinder- und Jugendmedizin Neuropaediatrie
    Jena, Germany
  • Klinik für Neuropädiatrie Universitätsklinikum Schleswig Holstein Campus Kiel
    Kiel, Germany
  • Kleinwachau Saechsisches Epilepsiezentrum Radeberggemeinnuetzige GmbH
    Radeberg, Germany
  • Universitaetsklinik fuer Kinder- und Jugendmedizin Abteilung III
    Tübingen, Germany
  • Schoen Klinik Vogtareuth Neuropaediatrie und Neurologische Rehabilitation, Epilepsiezentrum fuer Kinder und Jugendlische,Tagesklinik fuer Neuropaediatrie
    Vogtareuth, Germany
  • AOU Anna Meyer
    Firenze, 50139, Italy
  • Istituto Pediatrico Giannina Gaslini Dipartimento di Neurologia
    Genova, Italy
  • A.O Carlo Poma
    Mantova, 46100, Italy
  • Instituto Neurologica Carlo Besta
    Milano, 20133, Italy
  • Ospedale Fatebenefratelli e Oftalmico
    Milano, Italy
  • U.O. Neurologia Dipartimento di Neuroscienze Ospedale Pediatrico Bambino Gesù, IRCS
    Roma, 00165, Italy
  • Ospedal Policlinico Giambattista Rossi diBorga Roma
    Verona, 37134, Italy
  • Okayama University Hospital
    Okayama-shi, Okayama, Japan
  • Saitama Children's Medical Center
    Saitama-shi, Saitama, Japan
  • National Epilepsy Center Shizuoka Institute
    Shizuoka-city, Shizuoka, Japan
  • Tokyo Women's Medical University Hospital
    Shinjuku-ku, Tokyo, Japan
  • Hospital Sant Joande Déu
    Barcelona, Spain
  • Hospital Ruber Internacional Primera Planta Servicio de Neurologia
    Madrid, Spain
  • Clinica Universitaria de Navarra Fase 4. Segunda planta, Consulta de Pediatria
    Pamplona, Spain
  • Birmingham Children Hospital
    Birmingham, United Kingdom
  • Institute of Neurosciences Queens Elizabeth University Hospital
    Glasgow, United Kingdom
  • Alder Hey Hospital
    Liverpool, United Kingdom
  • Evelina Hospital
    London, United Kingdom
  • Great Ormonnd Street Hospital for Children NHS Foundation Trust
    London, United Kingdom
  • Sheffield Children's Hospital
    Sheffield, United Kingdom
09

References and documents

Publications

  • Sullivan J, Lagae L, Cross JH, Devinsky O, Guerrini R, Knupp KG, Laux L, Nikanorova M, Polster T, Talwar D, Ceulemans B, Nabbout R, Farfel GM, Galer BS, Gammaitoni AR, Lock M, Agarwal A, Scheffer IE; FAiRE DS Study Group. Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial. Epilepsia. 2023 Oct;64(10):2653-2666. doi: 10.1111/epi.17737. Epub 2023 Aug 17. PubMed 37543865 ↗
  • Cross JH, Galer BS, Gil-Nagel A, Devinsky O, Ceulemans B, Lagae L, Schoonjans AS, Donner E, Wirrell E, Kothare S, Agarwal A, Lock M, Gammaitoni AR. Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. Seizure. 2021 Dec;93:154-159. doi: 10.1016/j.seizure.2021.10.024. Epub 2021 Nov 2. PubMed 34768178 ↗
  • Sullivan J, Specchio N, Devinsky O, Auvin S, Perry MS, Strzelczyk A, Gil-Nagel A, Dai D, Galer BS, Gammaitoni AR. Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: A time-to-event analysis. Epilepsia. 2022 Jan;63(1):130-138. doi: 10.1111/epi.17106. Epub 2021 Oct 22. PubMed 34676542 ↗
  • Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, Devinsky O, Cross JH, Guerrini R, Talwar D, Miller I, Farfel G, Galer BS, Gammaitoni A, Mistry A, Morrison G, Lock M, Agarwal A, Lai WW, Ceulemans B; FAiRE DS Study Group. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019 Dec 21;394(10216):2243-2254. doi: 10.1016/S0140-6736(19)32500-0. Epub 2019 Dec 17. PubMed 31862249 ↗
  • Sullivan J, Perry MS, Wheless JW, Galer B, Gammaitoni A. Fenfluramine responder analyses and numbers needed to treat: Translating epilepsy trial data into clinical practice. Eur J Paediatr Neurol. 2021 Mar;31:10-14. doi: 10.1016/j.ejpn.2021.01.005. Epub 2021 Jan 22. PubMed 33540241 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Jul 2020, 54 months.

Results were first posted in Oct 2022, 2 years 2 months after primary completion.

Of 15 phase 3 interventional studies under Epilepsies, Myoclonic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 72. This study's 54 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2016
First posted
Feb 17, 2016
StartActual
Jan 15, 2016
Primary completionActual
Jul 29, 2020
CompletionActual
Jul 29, 2020
Results first posted
Oct 19, 2022
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02682927
Responsible party
Sponsor
First posted
Feb 17, 2016
Start date
Jan 15, 2016
Primary completion
Jul 29, 2020
Completion
Jul 29, 2020
Results posted
Oct 19, 2022
Last update
Sep 28, 2023

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenfluramine

Start the discussion